 REDWOOD CITY, Calif. BOSTON--BUSINESS WIRE--Adicet Bio, Inc. Nasdaq: ACET, a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor CAR T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in September. Details of the events are as follows: H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022, New York, New York An on-d 